Is Denali Therapeutics Inc (DNLI) overvalued? · $2.11B cap
Denali Therapeutics Inc (DNLI) is a biotechnology company listed on US.
This page asks whether Denali Therapeutics Inc (DNLI) looks expensive on cached numbers — not a short thesis.
Latest reported DNLI revenue for 2024-12-31 was $0. Net income was -$422.8M. Revenue was down 100.0% from 2023-12-31 to 2024-12-31. DNLI currently screens at market cap $2.11B.
DNLI currently screens at market cap $2.11B. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next DNLI 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the DNLI stock page for the full model, not this heading.
Not investment advice.